BPC-157 vs. TB-500: how the two peptides differ structurally

Why the names are easy to confuse

BPC-157 and TB-500 are both lyophilized peptide reference standards, but they are not close structural neighbours. <a href="/product/cp-030">BPC-157</a> is a 15-residue synthetic pentadecapeptide. <a href="/product/cp-031">TB-500</a> is a 43-residue, N-terminally acetylated thymosin beta-4 sequence. The useful comparison is therefore analytical: sequence length, molecular weight, terminal chemistry, HPLC profile, source-protein origin, and COA identity markers for in-vitro lot acceptance and release documentation review. [1]

Sequence length and origin

The first structural difference is size. BPC-157 is usually specified as the 15-residue sequence GEPPPGKPADDAGLV. Its calculated molecular weight is approximately 1419.5 Da for the free peptide. The sequence is described as a synthetic fragment related to gastric juice protective protein, and its COA identity line should be read as a defined pentadecapeptide identity check, not as a general family label. In a procurement file, the 15-residue length is one of the fastest ways to distinguish the material from longer thymosin-derived peptides. Note: 'TB-500' in the literature sometimes denotes the 7-residue LKKTETQ actin-binding fragment alone, but the Canada Peptides catalog entry (<a href="/product/cp-031">CP-031</a>) refers to the full-length 43-residue N-terminally acetylated thymosin beta-4. [2]

TB-500, by contrast, is commonly represented as full-length thymosin beta-4: a 43-residue, N-terminally acetylated actin-sequestering peptide with a molecular weight near 4963.4 Da. That size difference is large enough to change nearly every analytical readout. The exact mass moves from the low 1.4 kDa range to almost 5.0 kDa. The number of ionisable side chains increases. The chromatogram usually has a different retention window, and the MS deconvolution has more charge-state information to reconcile. [3]

The sequence-origin language also differs. BPC-157 is a synthetic fragment. TB-500 is tied to the thymosin beta-4 sequence class and contains the canonical LKKTETQ actin-binding motif. For a bench team comparing labels, this motif is a structural marker. It is not a performance claim. It is a seven-residue sequence feature that belongs in the identity section of a technical file alongside exact mass, purity method, lot number, and storage format. For broader COA terminology, see the guide to <a href="/research-guide/coa-vs-content-assay">reading a COA</a>. [4]

Residue composition and pH 7 charge

BPC-157 is compact and proline-rich. The sequence GEPPPGKPADDAGLV contains four prolines, two alanines, two aspartic acid residues, one lysine, one glutamic acid residue, one glycine pair across the sequence, and a terminal valine-leucine segment. At pH 7, the acidic side chains carry negative charge, lysine carries positive charge, and the free N-terminus and C-terminus contribute to the net charge calculation. A quick estimate places the molecule slightly negative to near neutral depending on the terminal form and counter-ion assignment. [5]

TB-500 has a wider residue spread because it is almost 3 times longer by residue count. The 43-residue chain includes multiple acidic residues, several lysine residues, hydrophobic residues such as leucine and isoleucine, and an N-terminal acetyl cap that removes the usual free alpha-amino contribution. At pH 7, the charge profile is therefore driven more by side-chain balance than by terminal charge. A technical comparison should report the predicted net charge from the exact supplied sequence rather than from the commercial name alone. [6]

Hydrophobicity is not just a single number. A Kyte-Doolittle window, a whole-sequence GRAVY score, and a reversed-phase retention observation can point in the same direction but are not identical measurements. BPC-157 has a short hydrophobic tail and a proline-dense middle. TB-500 distributes polar, charged, and hydrophobic residues across a longer chain. That distribution affects peak shape, interaction with C18 media, and desalting behaviour. A supplier COA should therefore give method context: column chemistry, gradient, detection wavelength, and identity method. [7]

Terminal chemistry and modifications

BPC-157 is generally handled as an unmodified linear pentadecapeptide unless the catalogue line states a salt or terminal variant. The standard <a href="/product/cp-030">CP-030 BPC-157</a> identity file should therefore be checked for sequence, molecular weight, purity by HPLC, water content where available, and counter-ion notes. A related salt-form comparison can involve <a href="/product/cp-032">BPC-157 Arginate</a>, where the sequence-level peptide identity is paired with a different salt form. That is a formulation and mass-accounting distinction, not a new 15-residue backbone. [8]

TB-500 has a structural modification that is central to identity: N-terminal acetylation. The acetyl cap adds 42.0106 Da relative to a free N-terminus and changes terminal charge behaviour. If a COA lists the sequence without showing the acetyl group, the mass should still make the modification visible. In HPLC-MS, a missing acetyl group would appear as a mass mismatch large enough to fail identity. In procurement language, this is the difference between accepting a family name and verifying the exact molecular species.

Neither comparison requires disulfide mapping. BPC-157 and TB-500 do not rely on intramolecular cystine bridges for their listed structures. That simplifies one part of characterisation: no reduced versus non-reduced disulfide confirmation is expected for either molecule. The more relevant checks are terminal state, exact mass, HPLC area-percent purity, water content, and counter-ion assignment. If a method file includes peptide mapping, the map should support the listed sequence and modification state rather than imply additional tertiary-structure complexity.

HPLC behaviour and impurity profile

A reversed-phase HPLC trace gives a practical structural fingerprint. BPC-157, at 15 residues and about 1.4 kDa, usually elutes in a shorter analytical window than a 43-residue thymosin beta-4 sequence under the same C18 gradient. The exact retention time is method-specific. A 5-95% acetonitrile gradient over 20 minutes cannot be compared directly with a 10-60% gradient over 45 minutes. What matters is the relation between the main peak, neighbouring peaks, detection wavelength, and MS-confirmed identity.

BPC-157 impurity patterns often reflect short-peptide synthesis issues: deletion sequences, incomplete coupling products, oxidation-sensitive trace peaks where applicable, and salt or water accounting outside the UV chromatogram. A proline-rich sequence can also show peak-shape quirks because cis-trans proline isomerisation may broaden or shoulder a main peak under some methods. That does not automatically invalidate the lot, but the COA should provide enough method detail to interpret whether the integrated main peak is a single dominant component.

TB-500 impurity interpretation is different because the molecule is longer. Longer solid-phase synthesis gives more opportunities for deletion variants and truncated sequences. The 43-residue chain may show a broader main peak, nearby truncation peaks, or deamidation and oxidation-related satellite peaks depending on method and storage history. For the chromatogram reader, the central question is whether the main peak is identity-confirmed by HPLC-MS and whether the area-percent purity calculation is reported with the same integration threshold used across lots. The article on <a href="/research-guide/reading-an-hplc-chromatogram">reading an HPLC chromatogram</a> is the useful companion piece.

Lyophilization and storage comparison

Both materials are normally supplied as lyophilized cakes or powder in sealed vials, so the first storage distinction is not usually the label name. It is vial condition and lyophilization quality. Inspect the cap, crimp, lot number, cake appearance, and COA match before logging the material into inventory. A smooth white lyophilizate with no visible moisture inside the glass is the expected receiving condition for a dry peptide reference standard. A collapsed cake, wet ring, broken seal, or mismatched COA should be escalated before the vial enters a working freezer.

The storage logic is also similar at the sealed-vial stage. Keep the vial protected from light, dry, and cold, typically at -20 °C unless the molecule-specific COA states a different condition. The size difference between 15 and 43 residues does not by itself create a universal storage rule. Method-qualified stability data, residual water, counter-ion form, seal integrity, and shipping history matter more. For receiving workflow detail, the cold-chain guide at <a href="/research-guide/peptide-storage-cold-chain">handling and storage</a> gives the broader SOP frame.

After reconstitution, the comparison becomes method-specific. A short pentadecapeptide stock and a longer thymosin beta-4 stock can differ in adsorption, aggregation, and analytical recovery. Those behaviours are not visible from the catalogue name alone. A lab should define diluent, concentration, container material, storage temperature, and maximum working-stock window in its own in-vitro protocol. The procurement record should capture those conditions separately from the supplier COA so later chromatograms are traceable to the handling conditions actually used.

What to check on a COA

A procurement lead can distinguish the two materials quickly by reading five COA lines. First, check sequence length: 15 residues for BPC-157 versus 43 for TB-500. Second, check exact mass: about 1419.5 Da versus about 4963.4 Da. Third, check terminal chemistry: free or stated salt form for BPC-157, N-terminal acetylation for TB-500. Fourth, confirm HPLC purity method and integration basis. Fifth, confirm HPLC-MS identity against the exact sequence, not just against a short product name.

The SKU layer should support, not replace, the chemistry. <a href="/product/cp-030">CP-030 BPC-157</a> and <a href="/product/cp-031">CP-031 TB-500</a> belong in different inventory records, with different molecular weights, different sequence strings, and different identity files. If a receiving team uses barcode labels, the mass and sequence should still appear in the technical dossier. A 3-character catalogue code can route the vial; it cannot prove the molecule.

The last check is language discipline. A structural comparison should not ask which material is better. It should ask whether the vial, COA, chromatogram, and mass spectrum all point to the same defined molecular species. That frame keeps the review objective. It also makes discrepancies easier to handle: a wrong mass, missing acetyl cap, unexplained peak shoulder, or salt-form mismatch becomes a documentable quality question rather than a subjective preference.

Summary

• BPC-157 is a 15-residue pentadecapeptide near 1419.5 Da; TB-500 is a 43-residue N-terminally acetylated thymosin beta-4 sequence near 4963.4 Da.

• The main structural checks are sequence, exact mass, terminal chemistry, HPLC area-percent purity, and HPLC-MS identity.

• TB-500 contains the LKKTETQ motif and an acetylated N-terminus; standard BPC-157 is shorter and usually unmodified unless a salt form is specified.

• For in-vitro inventory control, compare COA evidence and chromatograms rather than commercial shorthand.

FAQ

Are BPC-157 and TB-500 similar peptides by size?

No. BPC-157 is 15 residues and about 1419.5 Da, while TB-500 is 43 residues and about 4963.4 Da.

What is the fastest COA check to separate the two?

Check the sequence and exact mass first. A 15-residue, 1.4 kDa entry points to BPC-157; a 43-residue, nearly 5.0 kDa entry with N-terminal acetylation points to TB-500.

Does either peptide require disulfide-bond confirmation?

No routine disulfide map is expected for these listed structures because neither depends on an intramolecular cystine bridge.

Can HPLC retention time alone identify the material?

No. Retention time is method-dependent. Use it with HPLC-MS identity, sequence, molecular weight, and lot-specific COA data.

Frequently asked questions

References

1. Sikiric P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. · DOI
2. Yu F., Lin S., Morrison-Bogorad M. et al. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins.. Journal of Biological Chemistry. · DOI
3. Low T., Goldstein A. (1982). Chemical characterization of thymosin beta 4.. Journal of Biological Chemistry. · DOI
4. Merrifield R. (1963). Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. Journal of the American Chemical Society. · DOI
5. FIELDS G., NOBLE R. (1990). Solid phase peptide synthesis utilizing 9‐fluorenylmethoxycarbonyl amino acids. International Journal of Peptide and Protein Research. · DOI
6. Whitelegge J. (n.d.). HPLC and Mass Spectrometry of Intrinsic Membrane Proteins. HPLC of Peptides and Proteins. · DOI
7. Rozenski J., Chaltin P., Aerschot A. et al. (2002). Characterization and sequence confirmation of unnatural amino acid containing peptide libraries using electrospray ionization mass spectrometry. Rapid Communications in Mass Spectrometry. · DOI
8. Rauh M. (2012). LC–MS/MS for protein and peptide quantification in clinical chemistry. Journal of Chromatography B. · DOI